内分泌検査の世界市場：業界分析、規模、シェア、成長、動向、予測（2025年～2032年）

世界の内分泌検査の市場規模は、2025年に134億米ドルになるとみられ、2025年～2032年の予測期間に8.2%のCAGRで拡大し、2032年には232億米ドルに達すると予測されています。

内分泌検査市場には、さまざまな検査技術を用いたホルモンバランスの乱れや内分泌腺疾患の分析・診断が含まれます。これには、甲状腺機能、生殖ホルモン、糖代謝、副腎機能などの検査が含まれます。糖尿病、甲状腺障害、ホルモン性がんなどの内分泌関連疾患の増加に伴い、正確で迅速かつ利用しやすい検査ソリューションに対する需要が高まっています。イムノアッセイやタンデム質量分析を含む診断手法の技術的進歩は、内分泌診断に革命をもたらし、臨床転帰を改善しています。

世界の内分泌検査市場は、糖尿病、甲状腺機能亢進症、ホルモンバランスの乱れなどの内分泌疾患の急増によって推進されており、これらの疾患は、座りがちなライフスタイル、ストレス、高齢化によって増加傾向にあります。疾病の早期発見と定期的な健康モニタリングに対する意識の高まりにより、先進地域と発展途上地域の両方で診断検査量が大幅に増加しています。ハイスループット免疫測定法、質量分析法、バイオセンサーに基づく方法の統合といった診断技術の進歩は、検査の精度、スピード、手頃な価格をさらに向上させています。利便性と個別化ヘルスケアを求める患者の嗜好に後押しされ、在宅医療やポイントオブケアでの内分泌検査の適用が拡大していることも、市場成長を支える重要な要因です。

楽観的な見通しにもかかわらず、内分泌検査市場は一定の抑制要因に直面しています。先進的な診断プラットフォームや特殊な機器に関連する高コストが、中低所得地域では障壁となることが多いです。さらに、検査精度のばらつきや検査施設間の標準化の欠如は、診断結果に一貫性を欠くことにつながります。規制が複雑で、新しい診断ツールの承認プロセスに時間がかかることも、技術革新と導入のペースを遅らせる。さらに、多くの地域では熟練した検査技師が不足しており、検査サービスの質と信頼性に影響を及ぼしています。

内分泌検査市場は、個別化医療や予測診断へのシフトの高まりに起因する成長の機会に満ちています。技術革新は、小型化されたラボオンチップ装置、AI統合診断システム、マルチプレックスアッセイなど、感度の向上と迅速なターンアラウンドタイムを提供する次世代検査ソリューションの扉を開き続けています。特にアジア太平洋やラテンアメリカなどの新興国は、ヘルスケアインフラが整備され、患者の意識が高まっているため、未開拓の可能性を秘めています。診断薬企業とヘルスケアプロバイダーとの戦略的提携がイノベーションを促進し、遠隔地や十分なサービスを受けていない地域における内分泌検査へのアクセスを拡大しています。さらに、在宅検査キットや遠隔医療診断の台頭により、予測期間中、市場は大幅に拡大すると予想されます。

当レポートでは、世界の内分泌検査市場について調査し、検査別、技術別、適応症別、最終用途別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

• 市場の範囲と定義
• 市場力学
• COVID-19の影響分析
• 予測要因- 関連性と影響

第3章 付加価値のある洞察

第4章 世界の内分泌検査市場の見通し

• 主なハイライト
• 市場規模の分析と予測
  • 過去の市場規模分析、2019年～2024年
  • 現在の市場規模分析と予測、2025年～2032年
• 世界の内分泌検査市場の見通し：検査別
  • 過去の市場規模分析、検査別、2019年～2024年
  • 現在の市場規模分析と予測、検査別、2025年～2032年
  • 市場の魅力分析：検査別
• 世界の内分泌検査市場の見通し：技術別
  • 過去の市場規模分析、技術別、2019年～2024年
  • 現在の市場規模分析と予測、技術別、2025年～2032年
  • 市場の魅力分析：技術別
• 世界の内分泌検査市場の見通し：適応症別
  • 過去の市場規模分析、適応症別、2019年～2024年
  • 現在の市場規模分析と予測、適応症別、2025年～2032年
  • 市場の魅力分析：適応症別
• 世界の内分泌検査市場の見通し：最終用途別
  • 過去の市場規模分析、最終用途別、2019年～2024年
  • 現在の市場規模分析と予測、最終用途別、2025年～2032年
  • 市場の魅力分析：最終用途別

第5章 世界の内分泌検査市場の見通し：地域別

• 過去の市場規模分析、地域別、2019年～2024年
• 現在の市場規模分析と予測、地域別、2025年～2032年
  • 北米
  • ラテンアメリカ
  • 欧州
  • 東アジア
  • 南アジアとオセアニア
  • 中東・アフリカ
• 市場の魅力分析：地域別

第6章 北米の内分泌検査市場の見通し

第7章 欧州の内分泌検査市場の見通し

第8章 東アジアの内分泌検査市場の見通し

第9章 南アジア・オセアニアの内分泌検査市場の見通し

第10章 ラテンアメリカの内分泌検査市場の見通し

第11章 中東・アフリカの内分泌検査市場の見通し

第12章 競合情勢

• 市場シェア分析、2025年
• 市場構造
• 企業プロファイル（詳細- 概要、財務、戦略、最近の動向）
  • Abbott Laboratories, Inc.
  • AB Sciex Pte. Ltd.
  • Agilent Technologies, Inc.
  • bioMerieux SA
  • Bio-Rad Laboratories Inc.
  • DiaSorin SpA
  • F. Hoffmann-La Roche Ltd.
  • Laboratory Corporation of America Holdings（LabCorp）
  • Quest Diagnostics, Inc.
  • Thermo Fisher Scientific, Inc.
  • MP Biomedicals
  • Ortho-Clinical Diagnostics（QuidelOrtho Corporation）
  • Siemens Healthineers AG
  • Sysmex Corporation
  • その他

第13章 付録

Persistence Market Research has recently released a comprehensive report on the global Endocrine Testing Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

• Endocrine Testing Market Size (2025E): US$ 13.4 Bn
• Projected Market Value (2032F): US$ 23.2 Bn
• Global Market Growth Rate (CAGR 2025 to 2032): 8.2%

Endocrine Testing Market - Report Scope:

The endocrine testing market involves the analysis and diagnosis of hormonal imbalances and endocrine gland disorders using a range of laboratory techniques. This includes tests for thyroid function, reproductive hormones, glucose metabolism, and adrenal function, among others. With a rise in endocrine-related conditions such as diabetes, thyroid disorders, and hormonal cancers, the demand for accurate, rapid, and accessible testing solutions is escalating. Technological advancements in diagnostic methodologies, including immunoassays and tandem mass spectrometry, are revolutionizing endocrine diagnostics and improving clinical outcomes.

Market Growth Drivers:

The global endocrine testing market is being propelled by a surge in endocrine disorders, including diabetes, hyperthyroidism, and hormonal imbalances, which are on the rise due to sedentary lifestyles, stress, and aging populations. Growing awareness about early disease detection and regular health monitoring has significantly increased the volume of diagnostic testing across both developed and developing regions. Advancements in diagnostic technologies-such as the integration of high-throughput immunoassays, mass spectrometry, and biosensor-based methods-are further enhancing test precision, speed, and affordability. The expanding application of endocrine tests in home-based and point-of-care settings, fueled by patient preference for convenience and personalized healthcare, is another key driver supporting market growth.

Market Restraints:

Despite the optimistic outlook, the endocrine testing market faces certain limitations. High costs associated with advanced diagnostic platforms and specialized equipment often act as barriers in low- and middle-income regions. Moreover, variability in test accuracy and lack of standardization across laboratories can lead to inconsistent diagnostic outcomes. Regulatory complexities and the time-consuming approval process for new diagnostic tools also slow down the pace of innovation and adoption. Additionally, the shortage of skilled laboratory personnel in many regions affects the quality and reliability of testing services.

Market Opportunities:

The endocrine testing market is brimming with growth opportunities stemming from the increasing shift toward personalized medicine and predictive diagnostics. Technological innovation continues to open doors for next-generation testing solutions-such as miniaturized lab-on-a-chip devices, AI-integrated diagnostic systems, and multiplex assays-that offer enhanced sensitivity and rapid turnaround times. Emerging economies, particularly in Asia-Pacific and Latin America, present untapped potential due to their growing healthcare infrastructure and increasing patient awareness. Strategic collaborations between diagnostic companies and healthcare providers are fostering innovation and expanding access to endocrine testing in remote and underserved regions. Furthermore, the rise of at-home testing kits and telehealth diagnostics is expected to significantly broaden market reach over the forecast period.

Key Questions Answered in the Report:

• What are the primary factors driving the global endocrine testing market's growth?
• Which test types and technologies are gaining the most traction among healthcare providers?
• How are innovations in diagnostic tools impacting endocrine disease management?
• Who are the major players in the endocrine testing market, and what strategies are they employing?
• What are the regional trends and long-term projections for the endocrine testing market?

Competitive Intelligence and Business Strategy:

Leading players in the global endocrine testing market-including Abbott Laboratories, Agilent Technologies, Thermo Fisher Scientific, Quest Diagnostics, and F. Hoffmann-La Roche-are focusing on expanding their diagnostic portfolios with cutting-edge technologies. These companies are actively investing in R&D, automation, and AI-driven platforms to enhance test accuracy and workflow efficiency. Strategic acquisitions, collaborations with clinical laboratories, and partnerships with healthcare institutions are common strategies being employed to strengthen global reach. Companies are also developing patient-centric solutions, such as mobile-based testing kits and home-use devices, to cater to growing demand for decentralized diagnostics.

Companies Covered in This Report:

• Abbott Laboratories, Inc.
• AB Sciex Pte. Ltd.
• Agilent Technologies, Inc.
• bioMerieux SA
• Bio-Rad Laboratories Inc.
• DiaSorin S.p.A.
• F. Hoffmann-La Roche Ltd.
• Laboratory Corporation of America Holdings (LabCorp)
• Quest Diagnostics, Inc.
• Thermo Fisher Scientific, Inc.

Market Segmentation:

By Test:

• Testosterone Test
• Estradiol Test
• Thyroid Stimulating Hormone (TSH) Test
• Prolactin Test
• Luteinizing Hormone (LH) Test
• Progesterone Test
• Human Chorionic Gonadotropin (hCG) Hormone Test
• Insulin Test
• Others

By Technology:

• Tandem Mass Spectrometry
• Immunoassay
• Monoclonal & Polyclonal Antibody Technologies
• Clinical Chemistry Analyzers
• Others

By Disease Indication:

• Diabetes
• Hyperthyroidism
• Menopause
• Osteoporosis
• Cancer
• Others

By End Use:

• Hospitals
• Diagnostic Laboratories
• Ambulatory Care Centers
• Home-based Tests
• Specialty Centers
• Others

By Region:

• North America
• Europe
• East Asia
• South Asia and Oceania
• Latin America
• Middle East and Africa

Table of Contents

1. Executive Summary

• 1.1. Global Endocrine Testing Market Snapshot, 2025-2032
• 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. COVID-19 Impact Analysis
• 2.4. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Value Chain Analysis
• 3.2. Test Adoption / Usage Analysis
• 3.3. Government Initiatives & Funding in Endocrine Testing
• 3.4. Key Market Players
• 3.5. Regulatory Landscape
• 3.6. PESTLE Analysis
• 3.7. Porter's Five Force Analysis
• 3.8. Consumer Behavior Analysis

4. Global Endocrine Testing Market Outlook

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Bn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
  • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
• 4.3. Global Endocrine Testing Market Outlook: Test
  • 4.3.1. Historical Market Size (US$ Bn) Analysis, By Test, 2019-2024
  • 4.3.2. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
    • 4.3.2.1. Testosterone Test
    • 4.3.2.2. Estradiol Test
    • 4.3.2.3. Thyroid Stimulating Hormone (TSH) Test
    • 4.3.2.4. Prolactin Test
    • 4.3.2.5. Luteinizing Hormone (LH) Test
    • 4.3.2.6. Progesterone Test
    • 4.3.2.7. Human Chorionic Gonadotropin (hCG) Hormone Test
    • 4.3.2.8. Insulin Test
    • 4.3.2.9. Others
  • 4.3.3. Market Attractiveness Analysis: Test
• 4.4. Global Endocrine Testing Market Outlook: Technology
  • 4.4.1. Historical Market Size (US$ Bn) Analysis, By Technology, 2019-2024
  • 4.4.2. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 4.4.2.1. Tandem Mass Spectrometry
    • 4.4.2.2. Monoclonal & Polyclonal Antibody Technologies
    • 4.4.2.3. Clinical Chemistry
    • 4.4.2.4. Immunoassay
    • 4.4.2.5. Others
  • 4.4.3. Market Attractiveness Analysis: Technology
• 4.5. Global Endocrine Testing Market Outlook: Disease Indication
  • 4.5.1. Historical Market Size (US$ Bn) Analysis, By Disease Indication, 2019-2024
  • 4.5.2. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
    • 4.5.2.1. Diabetes
    • 4.5.2.2. Hyperthyroidism
    • 4.5.2.3. Menopause
    • 4.5.2.4. Osteoporosis
    • 4.5.2.5. Cancer
    • 4.5.2.6. Others
  • 4.5.3. Market Attractiveness Analysis: Disease Indication
• 4.6. Global Endocrine Testing Market Outlook: End-use
  • 4.6.1. Historical Market Size (US$ Bn) Analysis, By End-use, 2019-2024
  • 4.6.2. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 4.6.2.1. Hospitals
    • 4.6.2.2. Diagnotics Laboratories
    • 4.6.2.3. Ambulatory Care Centers
    • 4.6.2.4. Home-based Tests
    • 4.6.2.5. Speciality Centers
    • 4.6.2.6. Others
  • 4.6.3. Market Attractiveness Analysis: End-use

5. Global Endocrine Testing Market Outlook Region

• 5.1. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
• 5.2. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
  • 5.2.1. North America
  • 5.2.2. Latin America
  • 5.2.3. Europe
  • 5.2.4. East Asia
  • 5.2.5. South Asia and Oceania
  • 5.2.6. Middle East & Africa
• 5.3. Market Attractiveness Analysis: Region

6. North America Endocrine Testing Market Outlook

• 6.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 6.1.1. By Country
  • 6.1.2. By Test
  • 6.1.3. By Technology
  • 6.1.4. By Disease Indication
  • 6.1.5. By End-Use
• 6.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 6.2.1. U.S.
  • 6.2.2. Canada
• 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
  • 6.3.1. Testosterone Test
  • 6.3.2. Estradiol Test
  • 6.3.3. Thyroid Stimulating Hormone (TSH) Test
  • 6.3.4. Prolactin Test
  • 6.3.5. Luteinizing Hormone (LH) Test
  • 6.3.6. Progesterone Test
  • 6.3.7. Human Chorionic Gonadotropin (hCG) Hormone Test
  • 6.3.8. Insulin Test
  • 6.3.9. Others
• 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
  • 6.4.1. Tandem Mass Spectrometry
  • 6.4.2. Monoclonal & Polyclonal Antibody Technologies
  • 6.4.3. Clinical Chemistry
  • 6.4.4. Immunoassay
  • 6.4.5. Others
• 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
  • 6.5.1. Diabetes
  • 6.5.2. Hyperthyroidism
  • 6.5.3. Menopause
  • 6.5.4. Osteoporosis
  • 6.5.5. Cancer
  • 6.5.6. Others
• 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
  • 6.6.1. Hospitals
  • 6.6.2. Diagnotics Laboratories
  • 6.6.3. Ambulatory Care Centers
  • 6.6.4. Home-based Tests
  • 6.6.5. Speciality Centers
  • 6.6.6. Others
• 6.7. Market Attractiveness Analysis

7. Europe Endocrine Testing Market Outlook

• 7.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 7.1.1. By Country
  • 7.1.2. By Test
  • 7.1.3. By Technology
  • 7.1.4. By Disease Indication
  • 7.1.5. By End-use
• 7.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 7.2.1. Germany
  • 7.2.2. France
  • 7.2.3. U.K.
  • 7.2.4. Italy
  • 7.2.5. Spain
  • 7.2.6. Russia
  • 7.2.7. Rest of Europe
• 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
  • 7.3.1. Testosterone Test
  • 7.3.2. Estradiol Test
  • 7.3.3. Thyroid Stimulating Hormone (TSH) Test
  • 7.3.4. Prolactin Test
  • 7.3.5. Luteinizing Hormone (LH) Test
  • 7.3.6. Progesterone Test
  • 7.3.7. Human Chorionic Gonadotropin (hCG) Hormone Test
  • 7.3.8. Insulin Test
  • 7.3.9. Others
• 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
  • 7.4.1. Tandem Mass Spectrometry
  • 7.4.2. Monoclonal & Polyclonal Antibody Technologies
  • 7.4.3. Clinical Chemistry
  • 7.4.4. Immunoassay
  • 7.4.5. Others
• 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
  • 7.5.1. Diabetes
  • 7.5.2. Hyperthyroidism
  • 7.5.3. Menopause
  • 7.5.4. Osteoporosis
  • 7.5.5. Cancer
  • 7.5.6. Others
• 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
  • 7.6.1. Hospitals
  • 7.6.2. Diagnotics Laboratories
  • 7.6.3. Ambulatory Care Centers
  • 7.6.4. Home-based Tests
  • 7.6.5. Speciality Centers
  • 7.6.6. Others
• 7.7. Market Attractiveness Analysis

8. East Asia Endocrine Testing Market Outlook

• 8.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 8.1.1. By Country
  • 8.1.2. By Test
  • 8.1.3. By Disease Indication
  • 8.1.4. By End-Use
• 8.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 8.2.1. China
  • 8.2.2. Japan
  • 8.2.3. South Korea
• 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
  • 8.3.1. Testosterone Test
  • 8.3.2. Estradiol Test
  • 8.3.3. Thyroid Stimulating Hormone (TSH) Test
  • 8.3.4. Prolactin Test
  • 8.3.5. Luteinizing Hormone (LH) Test
  • 8.3.6. Progesterone Test
  • 8.3.7. Human Chorionic Gonadotropin (hCG) Hormone Test
  • 8.3.8. Insulin Test
  • 8.3.9. Others
• 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
  • 8.4.1. Tandem Mass Spectrometry
  • 8.4.2. Monoclonal & Polyclonal Antibody Technologies
  • 8.4.3. Clinical Chemistry
  • 8.4.4. Immunoassay
  • 8.4.5. Others
• 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
  • 8.5.1. Diabetes
  • 8.5.2. Hyperthyroidism
  • 8.5.3. Menopause
  • 8.5.4. Osteoporosis
  • 8.5.5. Cancer
  • 8.5.6. Others
• 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
  • 8.6.1. Hospitals
  • 8.6.2. Diagnotics Laboratories
  • 8.6.3. Ambulatory Care Centers
  • 8.6.4. Home-based Tests
  • 8.6.5. Speciality Centers
  • 8.6.6. Others
• 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Endocrine Testing Market Outlook

• 9.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 9.1.1. By Country
  • 9.1.2. By Test
  • 9.1.3. By Technology
  • 9.1.4. By Disease Indication
  • 9.1.5. By End-Use
• 9.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 9.2.1. India
  • 9.2.2. Indonesia
  • 9.2.3. Thailand
  • 9.2.4. Singapore
  • 9.2.5. ANZ
  • 9.2.6. Rest of South Asia & Oceania
• 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
  • 9.3.1. Testosterone Test
  • 9.3.2. Estradiol Test
  • 9.3.3. Thyroid Stimulating Hormone (TSH) Test
  • 9.3.4. Prolactin Test
  • 9.3.5. Luteinizing Hormone (LH) Test
  • 9.3.6. Progesterone Test
  • 9.3.7. Human Chorionic Gonadotropin (hCG) Hormone Test
  • 9.3.8. Insulin Test
  • 9.3.9. Others
• 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
  • 9.4.1. Tandem Mass Spectrometry
  • 9.4.2. Monoclonal & Polyclonal Antibody Technologies
  • 9.4.3. Clinical Chemistry
  • 9.4.4. Immunoassay
  • 9.4.5. Others
• 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
  • 9.5.1. Diabetes
  • 9.5.2. Hyperthyroidism
  • 9.5.3. Menopause
  • 9.5.4. Osteoporosis
  • 9.5.5. Cancer
  • 9.5.6. Others
• 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
  • 9.6.1. Hospitals
  • 9.6.2. Diagnotics Laboratories
  • 9.6.3. Ambulatory Care Centers
  • 9.6.4. Home-based Tests
  • 9.6.5. Speciality Centers
  • 9.6.6. Others
• 9.7. Market Attractiveness Analysis

10. Latin America Endocrine Testing Market Outlook

• 10.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 10.1.1. By Country
  • 10.1.2. By Test
  • 10.1.3. BY Technology
  • 10.1.4. By Disease Indication
  • 10.1.5. By End-Use
• 10.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 10.2.1. Brazil
  • 10.2.2. Mexico
  • 10.2.3. Rest of Latin America
• 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
  • 10.3.1. Testosterone Test
  • 10.3.2. Estradiol Test
  • 10.3.3. Thyroid Stimulating Hormone (TSH) Test
  • 10.3.4. Prolactin Test
  • 10.3.5. Luteinizing Hormone (LH) Test
  • 10.3.6. Progesterone Test
  • 10.3.7. Human Chorionic Gonadotropin (hCG) Hormone Test
  • 10.3.8. Insulin Test
  • 10.3.9. Others
• 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
  • 10.4.1. Tandem Mass Spectrometry
  • 10.4.2. Monoclonal & Polyclonal Antibody Technologies
  • 10.4.3. Clinical Chemistry
  • 10.4.4. Immunoassay
  • 10.4.5. Others
• 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
  • 10.5.1. Diabetes
  • 10.5.2. Hyperthyroidism
  • 10.5.3. Menopause
  • 10.5.4. Osteoporosis
  • 10.5.5. Cancer
  • 10.5.6. Others
• 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
  • 10.6.1. Hospitals
  • 10.6.2. Diagnotics Laboratories
  • 10.6.3. Ambulatory Care Centers
  • 10.6.4. Home-based Tests
  • 10.6.5. Speciality Centers
  • 10.6.6. Others
• 10.7. Market Attractiveness Analysis

11. Middle East & Africa Endocrine Testing Market Outlook

• 11.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 11.1.1. By Country
  • 11.1.2. By Test
  • 11.1.3. By Technology
  • 11.1.4. By Disease Indication
  • 11.1.5. By End-Use
• 11.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 11.2.1. GCC Countries
  • 11.2.2. Egypt
  • 11.2.3. South Africa
  • 11.2.4. Northern Africa
  • 11.2.5. Rest of Middle East & Africa
• 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
  • 11.3.1. Testosterone Test
  • 11.3.2. Estradiol Test
  • 11.3.3. Thyroid Stimulating Hormone (TSH) Test
  • 11.3.4. Prolactin Test
  • 11.3.5. Luteinizing Hormone (LH) Test
  • 11.3.6. Progesterone Test
  • 11.3.7. Human Chorionic Gonadotropin (hCG) Hormone Test
  • 11.3.8. Insulin Test
  • 11.3.9. Others
• 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
  • 11.4.1. Tandem Mass Spectrometry
  • 11.4.2. Monoclonal & Polyclonal Antibody Technologies
  • 11.4.3. Clinical Chemistry
  • 11.4.4. Immunoassay
  • 11.4.5. Others
• 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
  • 11.5.1. Diabetes
  • 11.5.2. Hyperthyroidism
  • 11.5.3. Menopause
  • 11.5.4. Osteoporosis
  • 11.5.5. Cancer
  • 11.5.6. Others
• 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
  • 11.6.1. Hospitals
  • 11.6.2. Diagnotics Laboratories
  • 11.6.3. Ambulatory Care Centers
  • 11.6.4. Home-based Tests
  • 11.6.5. Speciality Centers
  • 11.6.6. Others
• 11.7. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2025
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping by Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Abbott Laboratories, Inc.
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Sources
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. AB Sciex Pte. Ltd.
  • 12.3.3. Agilent Technologies, Inc.
  • 12.3.4. bioMerieux SA
  • 12.3.5. Bio-Rad Laboratories Inc.
  • 12.3.6. DiaSorin S.p.A.
  • 12.3.7. F. Hoffmann-La Roche Ltd.
  • 12.3.8. Laboratory Corporation of America Holdings (LabCorp)
  • 12.3.9. Quest Diagnostics, Inc.
  • 12.3.10. Thermo Fisher Scientific, Inc.
  • 12.3.11. MP Biomedicals
  • 12.3.12. Ortho-Clinical Diagnostics (QuidelOrtho Corporation)
  • 12.3.13. Siemens Healthineers AG
  • 12.3.14. Sysmex Corporation
  • 12.3.15. Others

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations